CN106860424A - A kind of Tadalafei fast release micropill preparation, preparation method - Google Patents
A kind of Tadalafei fast release micropill preparation, preparation method Download PDFInfo
- Publication number
- CN106860424A CN106860424A CN201710082466.4A CN201710082466A CN106860424A CN 106860424 A CN106860424 A CN 106860424A CN 201710082466 A CN201710082466 A CN 201710082466A CN 106860424 A CN106860424 A CN 106860424A
- Authority
- CN
- China
- Prior art keywords
- preparation
- tadalafei
- fast release
- medicine
- release micropill
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
Abstract
A kind of Tadalafei fast release micropill preparation, preparation method, are related to drug preparation technique and application field, and described fast release micropill preparation administering mode is oral administration, with blank capsule core as carrier.The Tadalafei fast release micropill preparation has the features such as medicine-feeding rate is high, content uniformity is good, and drug release is rapid, analgesic activity is rapid-action.Meanwhile, the fast release micropill preparation have Clinical practice compliance it is good, it is safe the features such as.Additionally, blank capsule core fluid bed medicine-feeding method is suitable to the preparation of extremely low specification Tadalafei drug oral preparation.
Description
Technical field
The present invention relates to drug preparation technique and application field, specifically related to a kind of Tadalafei fast release micropill preparation, system
Preparation Method and its application.
Background technology
Tadalafei（tadalafil）Also known as Xi Aili（Cialis）, there is more preferable selectivity to PDE5.In October, 2003
Listed in the U.S. first by Eli Lilly companies of the U.S., on October 6th, 2011, FDA (Food and Drug Adminstration)（FDA）Ratify him
Da Lafei (tadalafil, trade name Cialis) is used to treat benign prostatic hyperplasis (benign prostatic
Hyperplasia, BPH), the disease shows as prostatitis hylperadenosis.Tadalafei was approved for treating ED in 2003（Suddenly
Play dysfunction）, import, trade name have also been approved in China：Xi Aili.Erectile dysfunction is typically to indicate that stem can not reach
To, maintain to be enough to complete a kind of disease of rigidity required for a sexual intercourse, be commonly called as ED.The ED patient included in worldwide is about
There are 1.5 hundred million people, only the U.S. is more than 30,000,000.Cut-off 2011, global ED markets only have three medicines for treatment：Silaenafil,
Tadalafei and Vardenafil.Tadalafei is to work in these three ED medicines most fast, and duration of efficacy is most long, and it is unique not
The medicine influenceed by high fat diet and Ethanol intake.Silaenafil (being commonly called as " vigour ") is global first phosphodiesterase -5
Inhibitor, its business success not only increases understanding of the society to this disease, and causes that more male patients are happy to connect
By and actively seek treatment.But investigation finds, also only 10% erectile dysfunction male uses silaenafil now.It is huge
Do not receive treatment patient population indicate that ED pharmaceutical markets still suffer from huge commercial opportunity.Tadalafei (trade name
" Cialis " " Xi Aili ") and Vardenafil all be second generation phosphodiesterase 5 inhibitor, their listing again be such medicine
New vitality is injected in thing market, and for erectile dysfunction male provides, more side effects are smaller, clinical efficacy is clearly new
Selection.Tadalafei pharmacological action feature：Tadalafei it is oral through gastrointestinal absorption after, can be worked in 30 minutes, and curative effect
Continue 36 hours, be to work in current only three kinds of ED medicines most fast, duration of efficacy is most long, and unique not by fat high drink
Food and the medicine of Ethanol intake influence.Silaenafil and Vardenafil need to shift to an earlier date 3 hours and take, and duration of efficacy is no more than 1
Hour, alcohol and high fat diet influence the performance of drug effect.By these obvious drug effect advantages, Tadalafei is listing first year
Sales volume is that, more than 200,000,000 dollars, global marketing volume has broken through 18.7 hundred million dollars within 2011." cookle " medicine is easily ranked among
Ranks.U.S.'s listing has 4 kinds of specifications, and every is respectively 2.5 mg, 5 mg, 10 mg and 20 mg containing Tadalafei.
Micropill is a kind of spherical or spherical preparation of diameter in the range of 0.5~2.5mm, with drug release stabilization, it is reliable,
Uniformly, the advantages of good fluidity, capsule can be loaded or tablet is pressed into or other packagings supply Clinical practice.Micropill preparation is a kind of more single
First dosage disperses shape formulation, and a usual dosage is made up of tens to hundreds of pillers, compared with other one-pack types, micropill preparation clothes
Can be widely distributed in intestines and stomach after, medicine increases in intestines and stomach surface distributed area, it is to avoid medicine local concentration is excessive,
Not only increase drug bioavailability but also reduce the stimulation to intestines and stomach.
The preparation method of micropill is more, and wherein fluid bed pill method and extrusion-round as a ball pill method are that application is the widest at present
Two kinds of general microsphere and its preparations.Extrusion-spheronization is used for preparing load pill core or blank capsule core.Fluid bed pill method exists
Whole operations are completed in closed system, supplementary material is not suffered a loss, high with medicine-feeding rate, the features such as medicament contg is uniform, especially fitted
Together in the medicine-feeding of low content medicine.
The technical problem to be solved in the present invention is that drug half-life present in Tadalafei drug development is short, clinical practice
The problems such as injection poor compliance (cannot be administered orally).Tadalafei clinical practice treatment can be expanded by providing one kind
Window, and Orally-administrable, clinical compliance good preparation solve above-mentioned technical problem.
The content of the invention
The purpose of the present invention one is the Tadalafei fast release micropill preparation for providing a kind of Orally-administrable.Mesh of the invention
Two be that a kind of preparation method of Tadalafei fast release micropill preparation is provided.
To achieve the above object, solution of the invention is：A kind of Tadalafei fast release micropill preparation is provided, it is described
Fast release micropill preparation administering mode is oral administration, with blank capsule core as carrier, the Tadalafei water containing cosolvent and adhesive
Solution be upper drug solns, described Tadalafei consumption, according to weight ratio, Tadalafei consumption is the 0.0025% of the capsule core
~0.3%；The oral dose of Tadalafei is not higher than 20 micrograms.
Further, described blank capsule core is sucrose capsule core or microcrystalline cellulose capsule core.
Further, the cosolvent is selected from one or more in citric acid, acetic acid, hydrochloric acid, ascorbic acid.
Further, according to weight ratio, cosolvent consumption is the 20%~300% of Tadalafei.
Further, described adhesive be selected from Hydroxypropyl methylcellulose (HPMC), PVP (PVP), syrup, starch slurry,
One or more in carmethose, gelatin, Arabic gum, methylcellulose.
Further, according to weight ratio, binder dosage is the 0.18%~1.68% of blank capsule core.
Further, described any one Tadalafei fast release micropill preparation also includes overcoat membrane material；Described protection
Tunic material is selected from one or more in acrylic resin, Hydroxypropyl methylcellulose.
Further, described Tadalafei fast release micropill preparation, according to weight ratio, the consumption of overcoat membrane material is sky
The 1.0%~5.0% of white capsule core.
Further, described fast release micropill can be loaded on after capsule or addition proper auxiliary materials be pressed into after tablet orally to
Medicine.
To achieve the above object, solution of the invention is：A kind of preparation of Tadalafei fast release micropill preparation is provided
Method, is upper drug solns with the Tadalafei aqueous solution containing cosolvent and adhesive, using fluid bed with blank capsule core as carrier
Bottom is sprayed prescription method and prepares load medicine micropill, adds overcoat membrane material solution to obtain Tadalafei fast release micropill system through fluidized bed coating
Agent.
A kind of preparation method of Tadalafei fast release micropill preparation, including：
Step one：The preparation of upper drug solns；
Step 2：Spray medicine in fluid bed bottom；
Step 3：Fluidized bed coating-protection film layer；
Step 4：After dry.
Further, the step one is specially and weighs Tadalafei by formula, adds the citron acid solution of formula ratio molten
Solution, is then dissolved in being configured to quantitatively go up drug solns in the pure water solution for include adhesive.
Further, the step 2 is specially and the blank capsule core of formula ratio is placed in fluid bed, starts fluid bed, to
The upper drug solns prepared in quantitative input step one in fluid bed.
Further, fluid bed medicine-feeding parameter is set by the process conditions of optimization during drug solns in the input, including
150~180m3h-1 of fan delivery, 2~7rmin-1 of feed flow revolution speed, 25~40 DEG C of temperature of charge, atomizing pressure
0.16MPa。
Further, the step 3 is specially and prepares 5% overcoat membrane material solution by formula ratio, and fluidized bed coating parameter sets
150~180m3h-1 of fan delivery is set to, feed flow 5~15rmin-1 of revolution speed, temperature of charge is controlled in 25~30 DEG C, mist
Change pressure 0.3MPa.Further, the step 4 is specially after the completion of coating, adjusts fluid bed parameter, and coating micro-pill is in 30
~40 DEG C of 15~45min of fluidized drying.
Specific embodiment
The above of the invention is described in detail below in conjunction with specific embodiment, but this should not be interpreted as this hair
Bright technical scheme is only limitted to following examples.
The formula of embodiment 11
| Tadalafei | 50mg |
| Microcrystalline cellulose blank capsule core | 3000g |
| 0.3% acetum | 200ml |
| Hydroxypropyl methylcellulose (HPMC) | 300g |
| Talcum powder | 50g |
| Water | 5500g |
Preparation method：
(1) preparation of drug solns on：Tadalafei 50mg is weighed by formula, 0.3% acetum 200mL dissolvings is added, then
It is dissolved in the aqueous solution for including Hydroxypropyl methylcellulose (HPMC) 100g and is configured to drug solns on 1500g.
(2) medicine is sprayed at fluid bed bottom：Microcrystalline cellulose blank capsule core 3000g is placed in fluid bed, starts fluid bed, if
Put fluid bed medicine-feeding parameter:Fan delivery 150m3h-1, feed flow revolution speed 5rmin-1, temperature of charge control are 30~40
DEG C, atomizing pressure 0.16MPa, added medicine under fluidized state, after the completion of medicine-feeding, fluidized drying 15min.
(3) fluidized bed coating-protection film layer：Pure water 4100g is weighed by formula, is added into hydroxypropyl under the lower addition stirring of stirring
Methylcellulose (HPMC) 200g, stirs molten clear, and prepared concentration is 5% overcoat membrane material solution, adds talcum powder 50g, at a high speed
Emulsifying homogeneous 10 minutes, crossing 60 mesh sieves must protect film layer coating solution.Fluidized bed coating parameter is set：Fan delivery 180m3h-
1, feed flow revolution speed 15rmin-1, temperature of charge are controlled at 25~35 DEG C, and atomizing pressure 0.3MPa is prevented under fluidized state
Cuticular layer is coated.
(4) dry afterwards：After the completion of coating, coating micro-pill is in 30~40 DEG C of fluidized drying 30min.
The formula of embodiment 22
| Tadalafei | 100mg |
| Sucrose blank capsule core | 3000g |
| 0.1% citron acid solution | 300ml |
| PVP (PVP) | 8g |
| Acrylic resin | 200g |
| Water | 5000g |
Preparation method：
(1) preparation of drug solns on：Tadalafei 100mg is weighed by formula, 0.1% citron acid solution 300mL dissolvings is added, so
It is dissolved in afterwards in the aqueous solution for including PVP (PVP) 8g and is configured to drug solns on 1500g.
(2) medicine is sprayed at fluid bed bottom：Sucrose blank capsule core 3000g is placed in fluid bed, starts fluid bed, fluidisation is set
Bed medicine-feeding parameter:Fan delivery 150m3h-1, feed flow revolution speed 5rmin-1, temperature of charge control are in 30~40 DEG C, atomization
Added medicine under pressure 0.16MPa, fluidized state, after the completion of medicine-feeding, fluidized drying 15min.
(3) fluidized bed coating-protection film layer：Pure water about 3600g is weighed by formula, is added into acrylic resin under stirring
200g, stirs molten clear, and prepared concentration is 5% overcoat membrane material solution, and stirring is lower to add talcum powder 50g, high-speed emulsifying homogeneous
10 minutes, crossing 60 mesh sieves must protect film layer coating solution.Fluidized bed coating parameter is set：Fan delivery 180m3h-1, solution feed pump
Rotating speed 15rmin-1, at 25~35 DEG C, atomizing pressure 0.3MPa carries out protecting film layer bag under fluidized state for temperature of charge control
Clothing.(4) dry afterwards：After the completion of coating, coating micro-pill is in 30~40 DEG C of fluidized drying 30min.
The formula of embodiment 33
| Tadalafei | 150mg |
| Sucrose blank capsule core | 3000g |
| 0.6% hydrochloric acid solution | 700ml |
| Syrup | 70g |
| Acrylic resin | 200g |
| Water | 4500g |
Preparation method：
(1) preparation of drug solns on：Tadalafei 150mg is weighed by formula, 0.6% hydrochloric acid solution 700mL dissolvings is added, then
It is dissolved in the aqueous solution for including syrup 70g and is configured to drug solns on 1500g.
(2) medicine is sprayed at fluid bed bottom：Sucrose blank capsule core 3000g is placed in fluid bed, starts fluid bed, fluidisation is set
Bed medicine-feeding parameter:Fan delivery 150m3h-1, feed flow revolution speed 5rmin-1, temperature of charge control are in 30~40 DEG C, atomization
Added medicine under pressure 0.16MPa, fluidized state, after the completion of medicine-feeding, fluidized drying 15min.
(3) fluidized bed coating-protection film layer：Pure water about 3000g is weighed by formula, is added into acrylic resin under stirring
200g, stirs molten clear, and prepared concentration is 5% overcoat membrane material solution, addition talcum powder 60g, high-speed emulsifying homogeneous 10 minutes,
Crossing 60 mesh sieves must protect film layer coating solution.Fluidized bed coating parameter is set：Fan delivery 180m3h-1, feed flow revolution speed
15rmin-1, at 25~35 DEG C, atomizing pressure 0.3MPa carries out protection film layer and is coated under fluidized state for temperature of charge control.
(4) dry afterwards：After the completion of coating, coating micro-pill is in 30~40 DEG C of fluidized drying 30min.
The formula of embodiment 44
| Tadalafei | 5mg |
| Sucrose blank capsule core | 300g |
| 6% ascorbic acid solution | 100ml |
| Starch slurry | 0.8g |
| HPMC | 20g |
| Water | 500g |
Preparation method：
(1) preparation of drug solns on：Tadalafei 5mg is weighed by formula, 6% ascorbic acid solution 100mL dissolvings is added, then
It is dissolved in the aqueous solution for including starch slurry 0.8g and is configured to drug solns on 150g.
(2) medicine is sprayed at fluid bed bottom：Sucrose blank capsule core 300g is placed in fluid bed, starts fluid bed, fluidisation is set
Bed medicine-feeding parameter:Fan delivery 150m3h-1, feed flow revolution speed 2rmin-1, temperature of charge control are in 30~40 DEG C, atomization
Added medicine under pressure 0.16MPa, fluidized state, after the completion of medicine-feeding, fluidized drying 15min.
(3) fluidized bed coating-protection film layer：Pure water about 350g is weighed by formula, stirring is lower to add HPMC 20g, stirs molten
Clearly, prepared concentration is 5% overcoat membrane material solution, addition talcum powder 6g, high-speed emulsifying homogeneous 10 minutes, and crossing 60 mesh sieves must prevent
Cuticular layer coating solution.Fluidized bed coating parameter is set：Fan delivery 180m3h-1, feed flow revolution speed 5rmin-1, material temperature
At 25~35 DEG C, atomizing pressure 0.3MPa carries out protection film layer and is coated under fluidized state for degree control.
(4) dry afterwards：After the completion of coating, coating micro-pill is in 30~40 DEG C of fluidized drying 30min.
The formula of embodiment 55
| Tadalafei | 10mg |
| Sucrose blank capsule core | 3000g |
| 0.1% citric acid soln | 200ml |
| Carmethose | 70g |
| HPMC | 200g |
| Water | 5000g |
Preparation method：
(1) preparation of drug solns on：Tadalafei 10mg is weighed by formula, 0.1% citric acid soln 200mL dissolvings is added, so
It is dissolved in afterwards in the aqueous solution for including carmethose 70g and is configured to drug solns on 1500g.
(2) medicine is sprayed at fluid bed bottom：Sucrose blank capsule core 4000g is placed in fluid bed, starts fluid bed, fluidisation is set
Bed medicine-feeding parameter:Fan delivery 150m3h-1, feed flow revolution speed 5rmin-1, temperature of charge control are in 30~40 DEG C, atomization
Added medicine under pressure 0.16MPa, fluidized state, after the completion of medicine-feeding, fluidized drying 15min.
(3) fluidized bed coating-protection film layer：Pure water about 3500g is weighed by formula, stirring is lower to add HPMC 200g, stirring
Molten clear, prepared concentration is 5% overcoat membrane material solution, adds talcum powder 20g, high-speed emulsifying homogeneous 10 minutes to cross 60 mesh sieves
Film layer coating solution must be protected.Fluidized bed coating parameter is set：Fan delivery 180m3h-1, feed flow revolution speed 12rmin-1,
At 25~35 DEG C, atomizing pressure 0.3MPa carries out protection film layer and is coated under fluidized state for temperature of charge control.
(4) dry afterwards：After the completion of coating, coating micro-pill is in 30~40 DEG C of fluidized drying 30min.
Claims (10)
1. a kind of Tadalafei fast release micropill preparation, it is characterised in that described fast release micropill preparation administering mode is orally to give
Medicine, with blank capsule core as carrier, the Tadalafei aqueous solution containing cosolvent and adhesive is upper drug solns, described Tadalafei
Consumption, according to weight ratio, Tadalafei consumption is the 0.0025~0.3% of the capsule core；The oral dose of Tadalafei is not high
In 20 micrograms.
2. Tadalafei fast release micropill preparation as claimed in claim 1, it is characterised in that described blank capsule core is sucrose ball
Core or microcrystalline cellulose capsule core；The cosolvent is selected from one or more in citric acid, acetic acid, hydrochloric acid, ascorbic acid or presses
According to weight ratio, cosolvent consumption is the 20~300% of Tadalafei.
3. Tadalafei fast release micropill preparation as claimed in claim 1, it is characterised in that described adhesive is selected from hydroxypropyl first
One kind or many in cellulose, PVP, syrup, starch slurry, carmethose, gelatin, Arabic gum, methylcellulose
Kind, according to weight ratio, binder dosage is the 0.18~1.68% of blank capsule core.
4. any one Tadalafei fast release micropill preparation as described in claims 1 to 3, it is characterised in that also including overcoat
Membrane material；Described overcoat membrane material is selected from one or more in acrylic resin, Hydroxypropyl methylcellulose；According to weight ratio, prevent
The consumption of sheath membrane material is the 1.0~5.0% of blank capsule core.
5. any one Tadalafei fast release micropill preparation as described in Claims 1 to 4, it is characterised in that described quick-release is micro-
Ball is pressed into oral administration after tablet after being loaded on capsule or addition proper auxiliary materials.
6. a kind of preparation method of Tadalafei fast release micropill preparation, it is characterised in that with blank capsule core as carrier, with containing hydrotropy
The Tadalafei aqueous solution of agent and adhesive is upper drug solns, and spraying prescription method using fluid bed bottom prepares load medicine micropill, adds
Overcoat membrane material solution obtains Tadalafei fast release micropill preparation through fluidized bed coating.
7. a kind of preparation method of Tadalafei fast release micropill preparation, including：
Step one：The preparation of upper drug solns；
Step 2：Spray medicine in fluid bed bottom；
Step 3：Fluidized bed coating-protection film layer；
Step 4：After dry.
8. preparation method as claimed in claim 7, it is characterised in that the step one is specially and weighs Ta Dala by formula
It is non-, the citron acid solution dissolving of formula ratio is added, it is then dissolved in being configured to quantitative medicine-feeding in the aqueous solution for include adhesive molten
Liquid.
9. preparation method as claimed in claim 7, it is characterised in that the step 2 is specially the blank capsule core of formula ratio
It is placed in fluid bed, starts fluid bed, to the upper drug solns prepared in quantitative input step one in fluid bed, the input medicine-feeding
Fluid bed medicine-feeding parameter is set by the process conditions of optimization during solution, including 150~180m3h-1 of fan delivery, solution feed pump turn
2~7rmin-1 of speed, 25~40 DEG C of temperature of charge, atomizing pressure 0.16MPa.
10. preparation method as claimed in claim 7, it is characterised in that the step 3 is specially to be prepared 5% and prevent by formula ratio
Sheath membrane material solution, fluidized bed coating parameter is set to 150~180m3h-1 of fan delivery, 5~15rmin- of feed flow revolution speed
1, temperature of charge is controlled in 25~30 DEG C, atomizing pressure 0.3MPa；The step 4 is specially after the completion of coating, adjusts fluid bed
Parameter, coating micro-pill is in 30~40 DEG C of 15~45min of fluidized drying.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710082466.4A CN106860424A (en) | 2017-02-16 | 2017-02-16 | A kind of Tadalafei fast release micropill preparation, preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710082466.4A CN106860424A (en) | 2017-02-16 | 2017-02-16 | A kind of Tadalafei fast release micropill preparation, preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106860424A true CN106860424A (en) | 2017-06-20 |
Family
ID=59165994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710082466.4A Pending CN106860424A (en) | 2017-02-16 | 2017-02-16 | A kind of Tadalafei fast release micropill preparation, preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106860424A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107982258A (en) * | 2017-12-08 | 2018-05-04 | 佛山市腾瑞医药科技有限公司 | A kind of Febustat releases pellet preparations, preparation method |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103271885A (en) * | 2013-05-23 | 2013-09-04 | 浙江华海药业股份有限公司 | Tadalafil orally disintegrating tablet and preparation method thereof |
| CN106063780A (en) * | 2016-06-28 | 2016-11-02 | 国家海洋局第三海洋研究所 | A kind of tetradoxin fast release micropill preparation, preparation method and applications |
-
2017
- 2017-02-16 CN CN201710082466.4A patent/CN106860424A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103271885A (en) * | 2013-05-23 | 2013-09-04 | 浙江华海药业股份有限公司 | Tadalafil orally disintegrating tablet and preparation method thereof |
| CN106063780A (en) * | 2016-06-28 | 2016-11-02 | 国家海洋局第三海洋研究所 | A kind of tetradoxin fast release micropill preparation, preparation method and applications |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107982258A (en) * | 2017-12-08 | 2018-05-04 | 佛山市腾瑞医药科技有限公司 | A kind of Febustat releases pellet preparations, preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100549473B1 (en) | Fluoxetine Enteric Pellets | |
| CN100364501C (en) | Pharmaceutical composition of topiramate | |
| CN103417505B (en) | There is huperzine controlled release preparation of two-phase drug release behavior and preparation method thereof | |
| CN110035757A (en) | A kind of olaparib takes orally sustained and controlled release medicament composition and application thereof | |
| CN107595795A (en) | A kind of Metoprolol succinate sustained-release tablets and preparation method thereof | |
| CN101842087A (en) | Improved tablet coating | |
| CN102614220A (en) | Preparing method of paracetamol, caffein, atificial cow-bezoar and chlorphenamine maleate capsule content functional pellet | |
| CN106727420A (en) | A kind of net fast release micropill preparations of En Gelie, preparation method | |
| CN107982241B (en) | Potassium sodium dehydroandroan drographolide succinate enteric preparation and preparation method thereof | |
| WO2012018761A2 (en) | Method of treatment of androgen-mediated cancers | |
| CN106619567A (en) | Trelagliptin succinate rapid-release pellet preparation and preparation method thereof | |
| CN105496967B (en) | Ranitidine hydrochloride controlled release dry suspensoid agent and preparation method thereof | |
| CN102973515A (en) | Sustained release preparation for treating hypertention and angina, and preparation method thereof | |
| CN106860424A (en) | A kind of Tadalafei fast release micropill preparation, preparation method | |
| CN106727395A (en) | A kind of Apremilast fast release micropill preparation, preparation method | |
| CN101474166B (en) | Cetirizine and pseudoephedrine sustained-release capsule and preparation method thereof | |
| CN108014098A (en) | A kind of tolvaptan fast release micropill preparation, preparation method | |
| KR20010033206A (en) | Pharmaceutical compositions | |
| CN102247379A (en) | Compound preparation and preparation method thereof | |
| CN109200032A (en) | High drug load venlafaxine hydrochloride sustained-release pellet composition and spansule and preparation method | |
| CN103054932B (en) | Principal columns of a hall tree extract is preparing the application in treating Gastric Ulcer Treatment | |
| CN109646417A (en) | A kind of Trimetazidine sustained release tablets and preparation method thereof | |
| CN104688716B (en) | A kind of hydrochloric acid lorcaserin spansule and preparation method thereof | |
| CN107982268A (en) | A kind of tolvaptan preparation and its application | |
| CN105311024B (en) | Kushenin and its derivative are as the application prepared in treatment cutaneous vasculitis drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170620 |